JAC Advance Access published online on February 12, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh106
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brief report
1 Laboratoire de Botanique,
Cryptogamie et Biologie cellulaire, Faculté de Pharmacie,
13385 Marseille;
* Corresponding author. E-mail: anne.favel{at}pharmacie.univ-mrs.fr.
Received 22 September 2003
; revised 21 November 2003
; accepted 10 December 2003
Objectives: The aim of the present
study was to expand the MIC database for Candida lusitaniae in order to further determine its antifungal
susceptibility pattern. Methods: The activities of amphotericin B, fluconazole,
itraconazole, voriconazole and flucytosine were determined in
vitro against 80 clinical isolates of C. lusitaniae.
A set of 59 clinical isolates of Candida albicans and
of 51 isolates of Candida glabrata was included
to compare the susceptibilities to amphotericin B. The MICs were
determined by Etest with RPMI 1640 agar, and with both this medium
and antibiotic medium 3 (AM3) agar for testing of amphotericin B. Results: All isolates were highly susceptible
to fluconazole. The susceptibility to itraconazole was good; only
4% of isolates had dose-dependent susceptibility (MICs
0.25-0.5 mg/L). Voriconazole was very active in
vitro (100% of isolates were inhibited at Conclusion: C. lusitaniae appears
to be susceptible to amphotericin B, azole antifungal agents, and,
to a lesser extent, flucytosine.
Keywords: C. lusitaniae, antifungals,
susceptibility patterns, Etest
Susceptibility of clinical isolates of Candida
lusitaniae to five
systemic antifungal agents
2 Laboratoire
Central Hôpital Saint Joseph et Laboratoire de Microbiologie
CHU Nord, 13000 Marseille;
3 Service de Parasitologie-Mycologie,
Groupe Hospitalier Pitié-Salpêtrière,
75651 Paris;
4 Laboratoire
de Microbiologie, Hôpital Necker, 75015 Paris;
5 Laboratoire des Sciences végétales,
Faculté des Sciences pharmaceutiques et biologiques, 75006
Paris, France
0.094
mg/L). Flucytosine MICs ranged widely (0.004->32
mg/L). The set included 19% of flucytosine-resistant isolates.
For amphotericin B, 100% of isolates were inhibited at 0.75 mg/L (MIC50 0.047 mg/L;
MIC90 0.19 mg/L) and at 4
mg/L (MIC50 0.25 mg/L; MIC90 0.75 mg/L) on
RPMI and on AM3, respectively. A single isolate was categorized
as resistant to amphotericin B (MIC 0.75 and 4 mg/L on RPMI and
on AM3, respectively). Amphotericin B thus appeared very active in vitro against C. lusitaniae. Whatever
the test medium, the level of susceptibility of C. lusitaniae to
amphotericin B did not differ much from those of C.
albicans and C. glabrata.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. A. Pfaller and D. J. Diekema Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem Clin. Microbiol. Rev., January 1, 2007; 20(1): 133 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-R. Hsueh, Y.-J. Lau, Y.-C. Chuang, J.-H. Wan, W.-K. Huang, J.-M. Shyr, J.-J. Yan, K.-W. Yu, J.-J. Wu, W.-C. Ko, et al. Antifungal Susceptibilities of Clinical Isolates of Candida Species, Cryptococcus neoformans, and Aspergillus Species from Taiwan: Surveillance of Multicenter Antimicrobial Resistance in Taiwan Program Data from 2003 Antimicrob. Agents Chemother., February 1, 2005; 49(2): 512 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Pai and A. L. Jones Altered Susceptibility of Candida glabrata Bloodstream Isolates to Triazoles at Clinically Relevant pH Values: Comparison of the NCCLS M27-A2, Sensititre YeastOne, and Etest Methods Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4441 - 4443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Di Bonaventura, I. Spedicato, C. Picciani, D. D'Antonio, and R. Piccolomini In Vitro Pharmacodynamic Characteristics of Amphotericin B, Caspofungin, Fluconazole, and Voriconazole against Bloodstream Isolates of Infrequent Candida Species from Patients with Hematologic Malignancies Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4453 - 4456. [Abstract] [Full Text] [PDF]
|
|